Exelixis at Citi's Biopharma Conference: Strategic Growth and Innovation

Exelixis (NASDAQ:EXEL) presented at Citi’s Biopharma Back to School Conference, raising its net product revenue guidance to $2.1 billion after a strong first quarter. The company emphasized the continued growth of its flagship CABOMETYX, particularly in renal cell carcinoma and its recent launch for neuroendocrine tumors. Strategically, Exelixis is advancing its next-generation molecule, zanzalutinib, which showed positive results in the STELLAR-303 colorectal cancer trial, while discontinuing the head and neck cancer trial (305) to reallocate resources towards higher-value, less competitive indications, underscoring a disciplined approach to pipeline and franchise development.

Analysis

Exelixis (EXEL) demonstrated strong commercial execution and strategic pipeline management at the Citi Biopharma conference, leading to an upward revision of its 2025 net product revenue guidance midpoint to $2.1 billion. This revision is underpinned by the performance of its flagship drug, CABOMETYX, which continues to gain market share in renal cell carcinoma (RCC), growing by 4 percentage points year-over-year in Q2 2025 to reach 25% in first-line and over 45% in second-line settings. The company is expanding this franchise with a recent Q2 launch in neuroendocrine tumors (NET), where management targets a potential $1 billion addressable market. Strategically, Exelixis is advancing its next-generation molecule, zanzalutinib, which posted positive top-line results in the STELLAR-303 trial for colorectal cancer, a notable achievement in a difficult-to-treat setting. This progress is balanced by a disciplined approach to capital allocation, evidenced by the discontinuation of the STELLAR-305 trial in head and neck cancer to reallocate resources toward higher-value, less competitive indications. The pipeline strategy appears focused on creating distinct, non-cannibalizing franchises with zanzalutinib, with a pivotal trial in non-clear cell RCC (STELLAR-304) expected to read out in 2026, potentially generating first-in-class Level 1 evidence for that patient population.

Key Decisions for Investors

• Investors should recognize the continued momentum in the core CABOMETYX business, where sustained market share gains and the new NET launch support the upgraded revenue guidance, suggesting the franchise has not yet peaked.
• The full data disclosure from the positive STELLAR-303 trial for zanzalutinib in colorectal cancer represents a significant near-term catalyst; its clinical profile will be critical for assessing its franchise potential and competitive positioning.
• The discontinuation of the head and neck cancer trial should be viewed as a sign of disciplined resource management, as the company is prioritizing assets in less crowded markets, which may reduce risk and enhance the potential return on its R&D investment.
• Monitor the development of the non-clear cell RCC trial (STELLAR-304), as a positive outcome in 2026 could establish a new standard of care and create a defensible market for zanzalutinib, separate from CABOMETYX's primary indications.